Table 2.

Changes in the characteristics of the BAL cell infiltrate after treatment with the anti- G protein mAb 131-2G and the anti-F protein mAb 143-6C.

		Untreated	mAb 131-2G treated		mAb 143-6C treated

Days(pi)	Phenotype	Mean Number Cells [10³]±SE	Mean Number Cells [10³]±SE	% Reduction	Mean Number Cells [10³]±SE	% Reduction
4	CD3	42.01±0.17	34.56±0.53^*	17.73±0.93	33.86±1.20^*	19.38±3.18
	CD4	22.68±0.25	19.98±0.19^*	11.92±1.78	20.46±0.80	9.54±2.56
	CD8	19.33±0.42	14.59±0.34^*	24.52±0.14	13.41±0.40^**	30.56±3.55
	B cells	8.77±0.41	7.79±0.05^*	11.17±0.04	8.68±0.08^*	1.03±0.20
	Macrophage	8.88±0.04	4.93±0.71^*	44.46±7.83	6.56±0.24^**	26.03±2.99
	PMNs	9.67±0.13	2.04±0.71^**	78.90±2.11	8.80±0.06^*	8.99±0.34
	NK	47.31±0.14	28.94±1.26^**	38.82±2.83	42.93±1.22^*	9.27±2.33

5	CD3	71.28±2.66	36.06±0.83^*	49.32±3.06	68.74±0.14	3.48±3.40
	CD4	31.03±0.70	15.79±0.13^**	49.11±0.73	28.66±0.26	7.59±2.93
	CD8	24.88±0.05	9.81±0.31^**	61.49±2.41	24.78±0.09	2.82±2.64
	B cells	12.45±0.52	8.17±0.07^*	36.78±3.09	11.36±1.00	12.36±4.21
	Macrophage	17.43±0.31	6.96±0.24^**	60.03±2.09	14.98±0.50^*	14.00±4.40
	PMNs	6.90±0.35	1.97±0.09^**	67.43±4.53	6.11±0.58^*	19.78±3.56
	NK	71.04±3.16	29.31±1.43^**	58.61±3.85	62.99±1.56	11.13±6.14

6	CD3	74.83±0.79	38.12±0.20^**	49.05±0.27	68.30±2.17	8.74±1.93
	CD4	39.66±0.77	19.33±0.06^**	46.09±1.37	37.53±1.31	6.91±2.48
	CD8	24.47±0.97	13.19±0.33^**	51.26±0.79	22.77±0.60	5.39±1.48
	B cells	7.36±0.09	4.16±0.39^**	43.36±6.11	6.61±0.29	10.19±0.77
	Macrophage	15.33±0.21	10.19±0.38^*	33.56±1.57	10.13±0.58^*	33.92±2.88
	PMNs	3.56±0.21	2.54±0.03^*	28.66±0.69	2.65±0.14^*	25.72±4.03
	NK	73.35±3.09	36.04±0.23^**	50.79±2.39	34.09±1.67^**	53.38±4.24

7	CD3	76.94±1.93	38.72±1.20^**	49.62±2.82	65.77±2.00	14.12±0.46
	CD4	45.70±1.41	23.25±0.65^*	49.06±3.00	40.69±1.58	10.99±0.71
	CD8	25.48±4.55	10.69±0.64^**	49.68±3.76	17.13±0.33	19.47±0.38
	B cells	6.83±0.24	5.30±0.29^**	45.99±4.32	5.91±0.48	13.47±0.23
	Macrophage	15.58±0.31	9.44± 0.27^**	39.34±2.95	8.05±0.17^**	48.29±0.07
	PMNs	3.89±0.06	2.47±0.06^**	36.46±0.67	2.58±0.06^**	33.57±2.46
	NK	61.03±1.55	36.98±4.01^**	46.26±0.02	29.34±0.97^**	56.87±6.08

8	CD3	70.12±1.95	40.49±1.11^**	42.26±0.02	51.86±2.11^*	26.04±0.95
	CD4	42.17±0.97	24.25±0.66^**	42.50±0.25	30.72±1.22^*	27.17±1.21
	CD8	17.88±0.58	12.08±0.21^*	32.41±0.99	14.99±0.61^*	16.21±0.70
	B cells	8.42±0.20	3.38±0.09^**	59.93±0.14	4.34±0.16^**	48.52±0.67
	Macrophage	11.65±0.01	5.78±0.22^**	50.41±1.85	5.38±0.17^**	53.81±1.44
	PMNs	3.52±0.10	1.41±0.06^**	59.94±2.92	1.71±0.09^**	51.41±4.17
	NK	51.95±1.12	19.70±0.37^**	62.08±0.10	23.12±1.04^**	55.51±1.05

BALB/c mice were infected with r19F (1×10⁶ TCID₅₀) on day 0 and administered 300ug of anti-G (131-2G) or anti-F (143-6C) protein mAbs on day 3 pi (n=5 mice/group). Data are the mean total number of BAL cells by subtype at days 4-8 pi per lung: lymphocyte gate, anti-CD3+ (17A2), and anti-CD4+ (GK1.5) CD4 T cells; lymphocyte gate, CD3+ and anti-CD8+ (53-6.7) – CD8 T cells; CD3-, anti-CD45R/B220+ (RA3-6B2)- B cells; CD3-, anti-CD11b+ (M1/70)- macrophages, dendritic cells, and monocytes; CD3-, anti-mouse Ly06G/Gr-1 (RB6-8C5)- Polymorphonuclear cells (PMNs); CD3-, anti-mouse CD49b/Integrin alpha2 (DX5)- NK cell. The fold reduction is decrease in the number in treated relative to untreated mice for the cell type.

(p≤0.05, ANOVA)

^**

(p≤0.001, ANOVA) indicates significant decrease in numbers for untreated compared to mice receiving the indicated treatments. Results are representative of two independent experiments.